United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $544.60, for a total value of $5,173,700.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,063,379.80. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

United Therapeutics Price Performance

NASDAQ UTHR opened at $535.57 on Tuesday. The firm’s 50-day moving average is $555.98 and its two-hundred day moving average is $529.73. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The stock has a market capitalization of $22.73 billion, a P/E ratio of 19.77, a PEG ratio of 1.80 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period last year, the business earned $6.63 EPS. As a group, analysts anticipate that United Therapeutics Corporation will post 26.63 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. HC Wainwright raised their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Bank of America dropped their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday. Royal Bank Of Canada boosted their price objective on United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Finally, Morgan Stanley set a $516.00 target price on United Therapeutics in a research note on Thursday, May 7th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $644.82.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently modified their holdings of UTHR. Torren Management LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at $26,000. Activest Wealth Management grew its stake in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. Entrust Financial LLC acquired a new position in United Therapeutics during the 4th quarter worth $31,000. International Assets Investment Management LLC increased its holdings in United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB increased its holdings in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.